Methylprednisolone Pulse Therapy in COVID-19 as the First Choice for Public Health: When Right Timing Breaks Controversies—Emergency Guide

Abstract

According to the National Research Ethics Commission of the Federative Republic of Brazil-CNS Resolution No. 466 of 2012, this review does not require a consent form, as it does not present data that directly identify patients and because it is a theoretical research that it arises naturally from a professional practice that uses data that does not reveal the subjects/patients. Even so, the article is filed with the HSPE RESEARCH ETHICS COMMITTEE, via the Brazil research platform with approved dismissal. Consent to PublishManuscript has approved by HSPE Research Ethics Committee. Availability of Data and MaterialsAll data are available in the electronic medical record system of Hospital do Servidor Estadual (Sao Paulo-Brazil) and in the authors' research files. Author ContributionsLuiz Zanella wrote this article and elaborated Figure 1 based on the Biorender platform. He has been performing active participation in the management of COVID-19 patients. He wants to show that immune suppression in COVID-19 patients is responsible to reduced antibodies production.Luciana Galvão realised (still in the beginning) that COVID-19 patients need different management to overcome COVID-19 and have been working hard to pass way her experience ahead.We are Principal investigators "COVER-ME-UP" TRIAL (Methylprednisolone pulse).Daniela Paraskevopoulos: reviewed all articles and analysed their characteris-L. G. F. de Assis Barros D'Elia Zanella et al.